New article in the European Journal of Internal Medicine entitled “Treatment of systemic lupus erythematosus: Analysis of treatment patterns in adult and paediatric patients across four European countries”. The OMOP Team contributed their valuable insights on the topic of SLE treatment using the IQVIA Disease Analyzer Germany. Read more here: https://bit.ly/4efz5tH #RWE #OMOP #CDM
IQVIA
Hospitals and Health Care
Durham, North Carolina 2,095,022 followers
Accelerate innovation for a healthier world.
About us
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 86,000 employees, IQVIA conducts operations in more than 100 countries. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
- Website
-
https://www.iqvia.com/
External link for IQVIA
- Industry
- Hospitals and Health Care
- Company size
- 10,001+ employees
- Headquarters
- Durham, North Carolina
- Type
- Public Company
- Specialties
- Technology, Consulting, and Clinical Development
Locations
-
Primary
2400 Ellis Rd
Durham, North Carolina 27703, US
Employees at IQVIA
Updates
-
Facing challenges with clinical trial tech proliferation? IQVIA One Home for Sites is here to help. Join us in fixing the site plight and see how you can be part of the solution. https://bit.ly/4cR5fdM #LifeSciences #ClinicalTrials #HealthcareInnovation
-
Considering a move to #IQVIA but your dream job isn't available yet? Join our Global Talent Network and we will let you know when it is: https://bit.ly/3z3fL3T #WeAreIQVIA
-
Join us to hear industry experts Keith McDonald, Rama Mohan Rao Chikkam, Ankit Tyagi, Amar Tandon PMP®, and Raina Singh Paplikar discuss key strategies for the global development and market expansion of biosimilars and generics. Register now and be part of the conversation that shapes the future of biosimilars and generics!
Webinar Alert! Join us on Monday, September 16, 2024, at 7:30 am EST (5:00 pm IST) for an insightful webinar on Regulatory Strategies for Biosimilars and Generics for Global Success where industry experts will delve into key strategies for the global development and market expansion of biosimilars and generics. Register here https://lnkd.in/gQyjjrn6 now and be part of the conversation that shapes the future of biosimilars and generics! #RegulatoryStrategies #IQVIAWebinar Keith McDonald Rama Mohan Rao Chikkam Ankit Tyagi Amar Tandon PMP® Raina Singh Paplikar Murugan Durairaj
-
Oncology remains a powerhouse of innovation, with over 100 new cancer treatments expected to launch in the next five years. Download your copy of our latest white paper by authors Markus Gores and Stefan Lutzmayer for insights into novel therapeutic modalities and success factors for #oncology innovators. https://bit.ly/47iiHX8
-
Our new white paper provides valuable insights into how global health authorities are crafting the regulatory framework and offers practical guidance on leveraging AI/ML to improve trial efficiency, design, and outcomes.
Are you ready to unlock the future of drug development using AI/ML? Are you monitoring the current regulatory landscape for guidance on using GenAI in clinical trials? IQVIA’s Patrick Brady, PharmD, explores the transformative potential of AI and machine learning (ML) in clinical trials. The new white paper provides valuable insights into how global health authorities are shaping the regulatory framework and offers practical guidance on leveraging AI/ML to improve trial efficiency, design, and outcomes. Stay updated on emerging regulatory expectations and enhancing clinical trials: https://bit.ly/3Xmp6NF #drugdevelopment #GenAI #regulatorystrategy #regulatoryaffairs
-
President of IQVIA Real World Solutions Rob Kotchie takes 60 seconds to share his perspective on the magic of working at IQVIA, including our people, the breadth of our work, and the role you can play to make a positive impact on patient lives. Discover a career with greater purpose at IQVIA: https://bit.ly/4e7EJhk #WeAreIQVIA
-
Real World Evidence can improve cost and time efficiencies in healthcare decision-making, and the more we streamline our methods and approaches, the more we can take advantage of the benefits of RWE. This article by regulators and industry experts including IQVIA’s Christina Mack discusses a comprehensive framework for assessing RWE’s value that applies to all stakeholders, helping to optimize and improve decision-making. Laura Gressler Danica Marinac Dabic, MD, PhD, MMSc, FISPE Gregory Pappas MD PhD Frederic Resnic Stuart Williams, D.Sc., Kevin Yang Frank Weichold Christina Mack Paul Coplan Orestis Panagiotou https://bit.ly/3XujPDM
-
Are you prepared to navigate the complexities of IDMP? Read the new IQVIA customer case study on preparing for Identification of Medicinal Products success.
Are you prepared to navigate the complexities of IDMP through the Extended EudraVigilance Medicinal Product Dictionary (XEVMPD)? Our latest pharma case study offers practical approaches to achieving IDMP readiness and compliance. This comprehensive white paper guides you through the challenges and solutions for successful implementation, providing best practices for navigating the intricacies of XEVMPD. Read the case study to gain valuable insights and stay ahead: https://bit.ly/3YYYfrY #IDMP #XECMPD #regulatoryaffairs
-
Real world evidence is crucial for vaccine success. In our September 11 webinar, Innovation in vaccines and RWE, IQVIA’s Karin de Haart and GSK’s Rachel Reeves explore new advancements, including the first marketing approvals for RSV vaccines, and discuss the evolving role of RWE in vaccine development. https://bit.ly/4dH5HMN
Affiliated pages
Similar pages
Browse jobs
Stock
IQV
NYSE
20 minutes delay
$248.14
-0.7 (-0.281%)
- Open
- 249.54
- Low
- 244.4
- High
- 249.54
Data from Refinitiv
See more info on